30
Jun
2010
Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Cardiology, X - Inflammation, X - Oncology, X - Therapeutic Platform, XX - MA
Bind Biosciences (Cambridge, MA) a preclinical-stage nanoparticle platform company focused on increased efficacy and reduced toxicity of currently marketed drugs, closed a $12.4M Series C financing. Participants include Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.
14
Jun
2010
04
Jun
2010
12
Apr
2010
Posted in I - Series C, Q - 1Q10, R - NORTH EAST, X - Oncology, X - THx Delivery, X - Therapeutic Platform, XX - MA
Bind Biosciences (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on differential medicinal nanoengineered delivery of targeted therapeutics and controlled drug exposure to diseased tissue for various cancers, closed an $11M Series C financing. Participants have included DHK Investments, ARCH Venture Partners, Flagship Ventures, NanoDimension and Polaris Venture Partners.
05
Apr
2010
Posted in I - Series C, Q - 1Q10, R - INTERNATIONAL, X - Antibacterial, X - Therapeutic Platform
Aquapharm Biodiscovery (United Kingdom) a preclinical-stage discovery and development company focused on a marine based platform for the identification antimicrobial compounds, closed a $6.4M Series C financing. Participants include Aescap Venture, Tate & Lyle Ventures, Highlands and Islands Enterprise and NESTA.
01
Mar
2010
Posted in I - Series A, Q - 1Q10, R - INTERNATIONAL, X - Antibody, X - Therapeutic Platform
F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.
11
Feb
2010
Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - Antibody, X - Autoimmune, X - Oncology, X - Therapeutic Platform
arGEN-X (Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform with potential indications in autoimmunity, oncology and bone disease, closed a $4.5M Series A financing, bring total round proceeds to $18.3M. Participants have included Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, [...]
05
Feb
2010
Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA
Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]
04
Feb
2010
Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - DARPin, X - Opthalmology, X - Therapeutic Platform
Molecular Partners (Switzerland) a preclinical-stage developing DARPins, a potential new class of protein therapeutics focused on ophthalmology indications, closed a $45M Series B financing. Participants include Essex Woodlands Health Ventures, Index Ventures, Johnson & Johnson Development Corp., BB Biotech Ventures and EndeavourVision.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb
02
Feb
2010